ArticleGenes, chromosomes & cancer2008
The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.
Article in Genes, chromosomes & cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
196 citing papers in PubMed, 18 citations in OpenAlex.
- MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.British journal of cancer · 2013Trial
- Differential expression of microRNAs in GH-secreting pituitary adenomas.Diagnostic pathology · 2010Trial
- LAT1/SLC7A5-mediated amino acid uptake is regulated by redox signals triggered by formyl-peptide receptor 2.The FEBS journal · 2026Article
- Review
- Tumor-derived miR-126 promotes tumor progression through immune modulation beyond the local tumor environment.Frontiers in oncology · 2026Article
- MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- H3K27ac-activated LncRNA NUTM2A-AS1 Facilitated the Progression of Colorectal Cancer CellsCurrent cancer drug targets · 2024Article
- The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review.Global medical genetics · 2023Review
- Stage-specific treatment of colorectal cancer: A microRNA-nanocomposite approach.Journal of pharmaceutical analysis · 2023Review
- Can Dietary Actives Affect miRNAs and Alter the Course or Prevent Colorectal Cancer?International journal of molecular sciences · 2023Review
- Regulation and mechanism of action of miRNAs on insulin resistance in skeletal muscles.Non-coding RNA research · 2023Review
- Therapeutic Implications of microRNAs in Depressive Disorders: A Review.International journal of molecular sciences · 2022Review
- MEAHNE: miRNA-Disease Association Prediction Based on Semantic Information in a Heterogeneous Network.Life (Basel, Switzerland) · 2022Article
- Review
- Platelet-Derived miR-126-3p Directly Targets AKT2 and Exerts Anti-Tumor Effects in Breast Cancer Cells: Further Insights in Platelet-Cancer Interplay.International journal of molecular sciences · 2022Article
- Histone Modification on Parathyroid Tumors: A Review of Epigenetics.International journal of molecular sciences · 2022Review
- MiR-126-5p Promotes Tumor Cell Proliferation, Metastasis and Invasion by Targeting TDO2 in Hepatocellular Carcinoma.Molecules (Basel, Switzerland) · 2022Article
- Natural Herbal Medicine as a Treatment Strategy for Myocardial Infarction through the Regulation of Angiogenesis.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Metabolic reprogramming by miRNAs in the tumor microenvironment: Focused on immunometabolism.Frontiers in oncology · 2022Review
- Micro-ribonucleic acid modulation with oxidative stress and inflammation in patients with type 2 diabetes mellitus - a review article.Archives of medical science : AMS · 2022Article
136 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
MicroRNAs (miRNA/miR) are a class of small noncoding RNAs implicated in the pathogenesis of various malignancies. In the current study, using micro(RNA) arrays, we found a ubiquitous loss of miR-126 expression in colon cancer lines when compared to normal human colon epithelia. Reconstitution of miR-126 in colon cancer cells resulted in a significant growth reduction as evidenced in clonogenic assays. A search for miR-126 gene targets revealed p85beta, a regulatory subunit involved in stabilizing and propagating the phosphatidylinositol 3-kinase (PI3K) signal, as one of the potential substrates. Restoration of miR-126 in cancer cells induced a > or =3-fold reduction in p85beta protein levels, with no concomitant change in p85alpha, a gene that is functionally related to p85beta but not a supposed target of miR-126. Additionally, using reporter constructs, we show that the p85beta-3' untranslated region is directly targeted by miR-126. Furthermore, this miR-126 mediated reduction of p85beta was accompanied by a substantial reduction in phosphorylated AKT levels in the cancer cells, suggesting an impairment in PI3K signaling. Finally, in a panel of matched normal colon and primary colon tumors, each of the tumors demonstrated miR-126 down-regulation together with an increase in the p85beta protein level. Taken together, we propose that miR-126 regulates PI3K signaling partly by targeting p85beta, and that the loss of miR-126 may provide a selective growth advantage during colon carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.